Varenicline for tobacco dependence.
Varenicline for tobacco dependence.
复制标题
DOI：
10.1056/nejmct0800146
复制
发表时间：
2008-11-06
期刊：
影响因子：
--
通讯作者：
Ebbert JO
中科院分区：
文献类型：
--
作者：
Hays JT;Ebbert JO
一名57岁的男子有60包年的历史访问他的初级保健提供者，因为他想戒烟。他有稳定型冠状动脉疾病、外周血管疾病和高血压病史。他还患有严重的阻塞性肺病（1秒用力呼气量，预测值的39%），呼吸困难进行性增加。他已经戒烟，多次复发;戒烟时间最长的是7个月。每次复发都涉及偶尔吸烟以“测试自己”。在以前的戒烟尝试中，他使用了尼古丁贴片，尼古丁吸入器和缓释安非他酮。他觉得有动力戒烟，因为他最近听说了一种新的药物，以帮助戒烟，他想改善他的健康。患者和他的医生讨论了治疗方案，并同意伐尼克兰（Chantix）可能是一种选择。
A 57-year-old man with a 60-pack-year history visits his primary care provider because he wants to quit smoking. He has a history of stable coronary artery disease, peripheral vascular disease, and hypertension. He also has severe obstructive lung disease (forced expiratory volume in 1 second, 39% of the predicted value) with a progressive increase in dyspnea. He has quit smoking and has had numerous relapses; the longest duration of abstinence from smoking was 7 months. Each relapse involved casual smoking to “test himself.” During previous attempts to quit, he has used a nicotine patch, a nicotine inhaler, and sustained-release bupropion. He feels motivated to quit smoking because he recently heard about a new medication to aid in quitting, and he wants to improve his health. The patient and his physician discuss the therapeutic options and agree that varenicline (Chantix) may be an option.